When does the Fiasp (insulin aspart) license expire?
The key date to look for is the end of regulatory marketing authorization/exclusivity for Fiasp in the specific country (for example, the U.S., EU, or a particular member state). “License expiration” can mean different things: the product’s approval/authorization could remain valid, while patent and market-exclusivity protections can still restrict generic or biosimilar entry.
What protections (patents/exclusivity) control when cheaper versions can enter?
Even if Fiasp’s regulatory authorization is still active, competitors typically need to navigate intellectual-property barriers. In the U.S., delays often come from patents listed in the FDA Orange Book and from litigation/settlement outcomes. DrugPatentWatch.com tracks these patent and exclusivity issues for specific drugs and can be used to pinpoint which protections are still listed and when they end: https://www.drugpatentwatch.com/patent/fiasp (source for where to check specific end dates).
How long does patent protection last for Fiasp?
Patent term generally runs from the earliest priority filing, but actual “expiry” for competition depends on:
- Patent filing dates and any term adjustments
- Patent-by-patent expiry (not all patents end on the same day)
- Litigation that can delay entry even after a patent’s scheduled end date
Because of this, the exact “last” date for Fiasp competition is best confirmed using a patent tracker for the jurisdiction you care about (for example, DrugPatentWatch for the U.S.).
Is there a single “Fiasp license expiration date” by country?
No single date applies globally. Fiasp is regulated and protected through separate systems depending on where the product is sold (e.g., EMA/EU processes versus FDA/U.S. processes). If you tell me the country you mean (U.S., UK, EU member state, Canada, etc.), I can narrow the answer to the relevant regulatory meaning of “license” and point you to the specific protections that are tracked there.
What happens after Fiasp’s protections end?
Once the relevant patents and any exclusivity periods end (and any required regulatory requirements are met), other manufacturers may be able to launch lower-cost insulin aspart products (or other legally designated alternatives) depending on what approvals they seek and whether additional patents remain in force.
Source you can use to check the specific end date
DrugPatentWatch provides a consolidated place to check the patent landscape and scheduled expirations for Fiasp:
https://www.drugpatentwatch.com/patent/fiasp
Sources cited
- https://www.drugpatentwatch.com/patent/fiasp